

Immediate therapeutic efficacy of low-density lipoprotein apheresis for drug-resistant nephrotic syndrome: evidence from the short-term results from the POLARIS Study

Eri Muso · Masatoshi Mune · Tsutomu Hirano · Motoshi Hattori · Kenjiro Kimura · Tsuyoshi Watanabe · Hitoshi Yokoyama · Hiroshi Sato · Shunya Uchida · Takashi Wada · Tetsuo Shoji · Yukio Yuzawa · Tsukasa Takemura · Satoshi Sugiyama · Yoshiki Nishizawa · Satoru Ogahara · Noriaki Yorioka · Soichi Sakai · Yosuke Ogura · Susumu Yukawa · Yasuhiko Iino · Enyu Imai · Seiichi Matsuo · Takao Saito

Received: 20 June 2013 / Accepted: 28 May 2014
© Japanese Society of Nephrology 2014

Abstract

Background Hyperlipidemia is not merely a complication but a major exacerbating factor in longstanding nephrotic syndrome (NS). Low-density lipoprotein apheresis (LDL-A) has been reported to ameliorate dyslipidemia and induce rapid remission of NS. Several clinical studies have suggested the therapeutic efficacy of LDL-A, but the level of clinical evidence is insufficient. Therefore, a multicenter prospective study, POLARIS (Prospective Observational Survey on the Long-Term Effects of LDL Apheresis on Drug-Resistant Nephrotic Syndrome), was initiated in Japan. **Method** Patients with drug-resistant NS were prospectively recruited into the study and treated with LDL-A in facilities that were registered in advance. In the POLARIS study design, the clinical data are to be followed up for 2 years. In the current study, we aimed at evaluating the

short-term efficacy based on the treatment outcome of LDL-A immediately after completion of treatment.

Results Along with rapid improvement of hyperlipidemia, LDL-A significantly improved proteinuria and hypoproteinemia after treatment. More than half of the patients showed remission of NS based on the urinary protein level at the completion of LDL-A. The duration of NS before the start of treatment was significantly shorter in patients who responded to LDL-A.

Conclusions An analysis of patients registered in the POLARIS study indicated that LDL-A has short-term efficacy for drug-resistant NS. Rapid relief of dyslipidemia by LDL-A may provide early remission in about half of the NS patients who are resistant to conventional medication. Completion of the POLARIS study may reveal additional long-term effects of LDL-A in these patients.

E. Muso (✉)
Division of Nephrology and Dialysis, Kitano Hospital,
Tazuke Kofukai Medical Institute, 2-4-20 Ohgimachi,
Kita-ku, Osaka 530-8480, Japan
e-mail: muso@kitano-hp.or.jp

M. Mune
Ryoshukai Takaishi Fujii Hospital, Takaishi, Japan

T. Hirano
Department of Diabetes, Metabolism, and Endocrinology,
Showa University School of Medicine, Tokyo, Japan

M. Hattori
Department of Pediatric Nephrology, Tokyo Women's Medical
University, Tokyo, Japan

K. Kimura
Department of Nephrology and Hypertension, Internal Medicine,
St. Marianna University School of Medicine, Kawasaki, Japan

T. Watanabe
Department of Nephrology, Hypertension, Diabetology,
Endocrinology and Metabolism, Fukushima Medical University
School of Medicine, Fukushima, Japan

H. Yokoyama
Division of Nephrology, Kanazawa Medical University School
of Medicine, Uchinada, Japan

H. Sato
Department of Clinical Pharmacology and Therapeutics,
Graduate School of Pharmaceutical Sciences,
Tohoku University, Sendai, Japan

S. Uchida
Department of Internal Medicine, Teikyo University School of
Medicine, Tokyo, Japan

Keywords Short-term results · Drug-resistant nephrotic syndrome · LDL apheresis · Lipid nephrotoxicity

Introduction

Hyperlipidemia is a common complication of nephrotic syndrome (NS), with patients often having elevated serum levels of the so-called “malignant” lipoprotein species such as low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL), which contribute to vascular atherogenicity and subsequent organ injury. In NS, persistent elevation of these lipids in serum may exacerbate glomerular and tubulointerstitial damage, and in some cases, the clinical condition may deteriorate to end-stage renal failure (ESRD) [1]. To prevent progression of renal impairment, prompt lipid-lowering therapy for prolonged hyperlipidemia is required in patients with NS resistant to primary medication. HMG-CoA reductase inhibitors appear to be most effective among various lipid-lowering therapies and sometime provide remission of clinical symptoms of NS [2]; however, the effect is gradual and requires a long administration period [3].

LDL-A is a blood purification therapy that selectively removes apoprotein B-containing lipoproteins such as LDL from circulating blood and rapidly reduces the plasma cholesterol level. LDL-A was originally developed for prevention of progression of coronary atherosclerosis in patients with serious hyperlipidemia such as familial

hypercholesterolemia [4]. In the late 1980’s, LDL-A began to be used to improve dyslipidemia in NS, initially to prevent organ damage. However, LDL-A was found to improve both the dyslipidemic condition and clinical symptoms including proteinuria and hypoproteinemia [5].

Based on the early clinical outcomes, LDL-A became used as an adjunctive treatment in addition to medication. Several studies of LDL-A in patients with drug-resistant NS were performed and showed relatively favorable therapeutic effects [6, 7]. Muso et al. [8] found that patients with steroid-resistant NS showed marked reduction of the urinary protein (UP) level and elevation of serum albumin in more than 60 % of cases treated with LDL-A. To clarify whether these beneficial effects were attributable to LDL-A, the K-FLAT (Kansai FGS LDL Apheresis Treatment) study was conducted as a multicenter controlled trial using a fixed protocol of comparison of combination therapy of steroids and LDL-A with steroid therapy alone. This study showed that combination therapy had more beneficial effects than steroid monotherapy, with more rapid relief from NS and a significantly higher remission rate after two years of therapy [9, 10].

Following these results, the Japanese Society of Kidney and Lipids Research performed a nationwide survey to examine the therapeutic effects of LDL-A for NS in actual clinical practice, and showed that LDL-A was a highly effective mid- and long-term treatment [11]. However, these results had the limitation that the data were obtained from a retrospective questionnaire survey based on the case reports. To establish more clear-cut evidence for the efficacy of LDL-A, we

T. Wada
Department of Laboratory Medicine, Kanazawa University
Graduate School of Medicine, Kanazawa, Japan

T. Shoji · Y. Nishizawa
Department of Metabolism, Endocrinology and Molecular
Medicine, Osaka City University Graduate School of Medicine,
Osaka, Japan

Y. Yuzawa
Department of Nephrology, Fujita Health University School of
Medicine, Toyoake, Japan

T. Takemura
Department of Pediatrics, Kinki University School of Medicine,
Osaka-Sayama, Japan

S. Sugiyama
Division of Nephrology, Kanayama Clinic, Nagoya, Japan

S. Ogahara
Division of Nephrology and Rheumatology, Department of
Internal Medicine, Fukuoka University, Fukuoka, Japan

N. Yorioka
Department of Advanced Nephrology, Graduate School of
Biomedical Science, Hiroshima University, Hiroshima, Japan

S. Sakai · Y. Ogura
The Kidney Foundation, Japan, Tokyo, Japan

S. Yukawa
Wakayama KD Clinic, Wakayama, Japan

Y. Iino
Department of Nephrology, Nippon Medical School, Tokyo,
Japan

E. Imai
Nakayamadera Imai Clinic, Takarazuka, Japan

S. Matsuo
Department of Nephrology, Nagoya University Graduate School
of Medicine, Nagoya, Japan

T. Saito
Faculty of Medicine, General Medical Research Center, Fukuoka
University, Fukuoka, Japan

conducted a prospective trial named the POLARIS (Prospective Observational Survey on the Long-Term Effect of LDL Apheresis on Drug-Resistant Nephrotic Syndrome) study. The goal of the POLARIS study is to investigate the short-, mid- and long-term outcomes for 2 years after treatment, and the patients are currently being followed up. In this report, we examined outcomes immediately after LDL-A treatment in patients in the POLARIS study to evaluate the short-term therapeutic efficacy of LDL-A and to identify the factors that influence this efficacy.

Methods

Study design and patient population

The POLARIS study is a prospective, observational, multicenter, cohort study based on a central registration system. The study protocol was registered and disclosed on the web site (<http://www.umin.ac.jp/>) of the University Medical Information Network (UMIN), Japan (ID: UMIN00000871). In principle, investigators obtained an internal review board (IRB) approval before participating in the study. Otherwise, the IRB approvals in the facilities where the principal investigators belong (Kitano Hospital: 06-12-011 for E. M. and Fukuoka University: 6-110 for T. S.) acted for them in the case that an IRB was not organized.

Since the POLARIS study is an observational study and intended to reveal actual efficacy of LDL-A in combination with standard therapy in ordinary clinical practice, the protocol does not intervene with each patient's treatment course. Therefore, actual treatment regimen of each episode was left to the discretion of the individual attending doctors. During 2 years of registration period, a total of 64 episodes of LDL-A treatment in 58 patients with NS who were resistant to primary medication, which is generally full-dose steroids or saturated cyclosporine A treatment for at least 4 weeks, and considered by their attending doctor to be a candidate for LDL-A treatment were prospectively registered in the POLARIS study before the treatment started. Each patient was informed of the outline of the study and the risks and benefits of LDL-A before enrollment, and then registered in the study with written informed consent. Although the type of LDL-A modality was not specified in the protocol, dextran sulfate cellulose column adsorption technique (Liposorber LA-15, Kaneka Corporation, Osaka, Japan) was used in all cases.

In the current study, the short-term efficacy of LDL-A in addition to prior medication was evaluated in patients with NS in whom the proteinuria level was not reduced to <1.0 g/day after the initial treatment for at least 4 weeks, although the original study design stipulates that the clinical outcome of the patients will be followed for

2 years after the treatment. Of the 64 episodes originally registered in the POLARIS study, 17 episodes were excluded from analysis in the current study for the following reasons: lack of UP data in 7 episodes, UP data estimated from the UP/urinary creatinine ratio of casual urine in 7 episodes, UP level already reduced to <1.0 g/day at the initiation of LDL-A in 7 episodes, and treatment with LDL-A less than 4 weeks after primary medication in 2 episodes. Therefore, short-term clinical data for 47 episodes in 44 patients were analyzed in this study. Clinical data for these patients were collected at initiation and after completion of LDL-A. The UP data analyzed in the study were evaluated in 24-h urine.

Laboratory findings

Clinical parameters were evaluated based on the data collected by attending doctors at the initiation and completion of LDL-A in the respective facilities. Practical measurement of parameters was entrusted to the doctors at each facility.

Statistical analysis

Comparison of clinical parameters between before and after LDL-A, and between effective and non-effective episodes were analyzed by the paired *t* test and Student's *t* test, respectively. Evaluation of factors that affect treatment outcome was analyzed by Chi-square test or Fischer's exact test. $p < 0.05$ was taken as significant. Data were expressed as mean \pm SD.

The definition of clinical efficacy

The short-term clinical efficacy was evaluated on a three-category scale based on the UP level before initiation of LDL-A and within four weeks after completion of LDL-A, as follows: very effective, the UP level before LDL-A was ≥ 3.5 g/day and was reduced to <1.0 g/day after LDL-A; effective, the UP level before LDL-A was ≥ 3.5 g/day and was reduced to <3.5 g/day (but ≥ 1.0 g/day) after LDL-A, or the UP level before LDL-A was <3.5 g/day (but ≥ 1.0 g/day) and was reduced to <1.0 g/day after LDL-A; non-effective, cases other than those in which LDL-A was judged to be very effective or effective.

Results

Characteristics of patients and episodes

The characteristics of the 47 episodes and 44 patients are shown in Table 1. The average number of LDL-A sessions was 9.6 times for each treatment and the average amount of

Table 1 Patient and episode characteristics

| | |
|---|--------------------|
| Patient characteristics | |
| Total number | 44 |
| Age (mean \pm SD) (years) | 55.4 \pm 17.3 |
| Age (range) (years) | 18–84 |
| Gender (male/female) | 27/17 |
| Episode characteristics | |
| Total number | 47 |
| Renal biopsy (\pm) | 41/6 |
| First time/recurrent | 27/19 * |
| Average number of LDL-A sessions | 9.6 |
| Average amount of plasma per session [L] | 3.5 L |
| Concomitant drugs | |
| Cyclosporine A administration (\pm) | 24/22 ^a |
| Steroid pulse therapy (\pm) | 4/42 ^a |
| Diuretics administration (\pm) | 26/21 |
| ARB ^b administration (\pm) | 29/18 |
| Anti-platelet agents (\pm) | 31/16 |
| Ant-coagulant (\pm) | 17/30 |

^a Data were not collected for one episode

^b Angiotensin II receptor blocker

Table 2 Classification of primary diseases

| Disease | Episodes | Patients |
|---|----------|-----------------|
| Focal segmental glomerulosclerosis ^a | 26 | 23 ^a |
| Membranous nephropathy | 4 | 4 |
| Henoch-Schönlein purpura nephritis | 3 | 3 |
| Minimal change nephrotic syndrome | 2 | 2 |
| Renal amyloidosis | 2 | 2 |
| Others ^b | 5 | 5 |
| Uncertain | 5 | 5 |

^a Including three patients complicated with other renal diseases (membranous nephropathy 2, diabetic nephropathy 1)

^b Membranoproliferative glomerulonephritis; crescentic glomerulonephritis; IgA nephropathy; lupus nephropathy; hepatitis B virus-associated nephropathy

3.5 L of plasma was treated in each session. The primary diseases of the patients are shown in Table 2. Focal segmental glomerulosclerosis (FSGS) was the most frequent primary disease, presenting in 23 patients (52.3 %). The other patients had a variety of primary diseases.

Effects of LDL-A on serum and urine parameters

The clinical parameters before and after the course of LDL-A treatment are shown in Table 3. The serum total protein (SP) and serum albumin (SA) levels increased significantly after LDL-A and the reduction of the UP level was also

significant. The LDL cholesterol (LDL-c) level decreased by more than 50 % and total cholesterol (TC) was also reduced significantly after LDL-A. Significant decreases of fibrinogen (Fb) and thrombin-antithrombin III complex (TAT) were also observed.

The changes in UP, SP, and SCr levels in individual episodes from before to after LDL-A are shown in Fig. 1. The UP and the SCr levels decreased in 76.6 % (36/47) and 56.5 % (26/46) of the episodes, and the SP level increased in 53.2 % (25/47) of the episodes.

We also evaluated the change in UP level before and after LDL-A in each primary disease of NS (Table 4). Since types of primary diseases were wide-ranging and the number of episodes with those other than FSGS (non-FSGS) was small (1–4 at most), it is considered to be difficult to review the trend of UP reduction in each type of diseases. However, as a whole, even episodes with non-FSGS showed almost equivalent level of UP to those with FSGS both in before and after LDL-A.

Evaluation of the clinical efficacy of LDL-A

The short-term clinical efficacy of LDL-A was evaluated using the UP level derived from 24-h urine at completion of the treatment. LDL-A was evaluated as very effective in 10/47 episodes (21.3 %) and effective in 15 (31.9 %). Therefore, 25 (53.1 %) episodes were treated effectively. LDL-A was judged to be non-effective in the other 22 (46.8 %) episodes, including some in which the UP level increased after LDL-A.

The percentage of episodes in which LDL-A was clinically effective (i.e., the total of very effective and effective) was 53.8 % (14/26) in cases with FSGS as the primary disease. A similar rate of 50 % (8/16) was found for episodes derived from primary diseases other than FSGS.

Factors that affect clinical efficacy

The factors examined in this study including the patient and the episode characteristics, and the level of clinical parameters, were compared between effective and non-effective treatments (Tables 5 and 6). Almost all the factors were not likely to be associated with clinical efficacy. However, the level of SP at pre-treatment was significantly higher ($p = 0.049$, Student's t test) and also that of UP showed higher trend ($p = 0.075$, Student's t test) in effective treatments than in non-effective. In addition, the rate of episodes in which LDL-A treatment started within 8 weeks after the onset of NS was significantly higher than those in which it took 8 weeks or longer (48.8 vs. 5.3 %, $p = 0.012$, Chi-square test) implying that the earlier the treatment is applied, the more likely effective treatment is obtained.

Table 3 Clinical parameters before and after LDL-A treatment

| Clinical parameter | Unit | n | Before | After | p value |
|---|----------|----|-----------------|-----------------|---------|
| Serum total protein (SP) | (g/dL) | 46 | 4.42 ± 0.69 | 4.68 ± 0.81 | <0.05 |
| Serum albumin (SA) | (g/dL) | 47 | 2.15 ± 0.63 | 2.63 ± 0.79 | <0.01 |
| Serum creatinine (SCr) | (mg/dL) | 47 | 1.82 ± 1.60 | 1.62 ± 1.57 | n.s. |
| Creatinine clearance (CCr) | (mL/min) | 23 | 58.59 ± 41.35 | 65.11 ± 41.39 | <0.05 |
| Urinary protein (UP) | (g/day) | 47 | 6.28 ± 2.96 | 3.46 ± 3.34 | <0.01 |
| Triglyceride (TG) | (mg/dL) | 40 | 262.74 ± 155.17 | 241.30 ± 182.14 | n.s. |
| Total cholesterol (TC) | (mg/dL) | 40 | 331.10 ± 113.25 | 210.38 ± 77.42 | <0.01 |
| LDL cholesterol (LDL-c) | (mg/dL) | 38 | 205.86 ± 100.84 | 92.37 ± 56.64 | <0.01 |
| HDL-cholesterol (HDL-c) | (mg/dL) | 34 | 69.49 ± 22.58 | 73.64 ± 23.40 | n.s. |
| Fibrinogen (Fb) | (mg/dL) | 28 | 374.46 ± 130.04 | 297.92 ± 108.87 | <0.01 |
| Thrombin-antithrombin III complex (TAT) | (ng/mL) | 18 | 16.39 ± 33.60 | 12.21 ± 34.10 | <0.05 |




Fig. 1 Changes in UP (a), SP (b), and SCr (c) levels from before to after LDL-A in individual episodes. The UP and SCr levels decreased in 37 (69.6 %) and 27 (55.4 %) of the 47 episodes, respectively, and

the SP level increased in 30 (60.0 %) of 46 episodes (data were not collected in one episode)

Discussion

The POLARIS study was designed as a prospective cohort study to evaluate clinical efficacy of LDL-A. In the actual clinical practice, LDL-A treatment is usually applied as an adjunctive therapy in the case that patients did not respond to standard medication and often had no option left and we considered that it was difficult not only to intervene with each patient's treatment prescription but also to conduct a controlled study with non-treatment group in which the patients could reach serious stage. Therefore, the study was conducted as an observational, cohort study. In this report, we examined the short-term efficacy at a point immediately after treatment among the patients registered in the POLARIS study. Clinical efficacy was evaluated based on the recovery of a patient from the nephrotic state. Analysis of short-term clinical data showed efficacy of LDL-A in more than half of the episodes (25/47, 53.1 %) with relief

from the nephrotic state as early as four weeks after treatment.

Muso et al. found that LDL-A for steroid-resistant NS decreased the UP level in 6 (66.7 %) of 11 episodes at 2 weeks after treatment [8]. Muso and colleagues then confirmed the clinical efficacy of LDL-A in the K-FLAT study, in which LDL-A in combination with steroids reduced the UP level to <3.5 g/day in 13 (76.4 %) of 17 episodes within one or 2 weeks after treatment, whereas only 5 (50 %) of 10 episodes achieved the same UP level with steroid treatment alone [9, 10]. Hattori et al. used LDL-A in pediatric patients with steroid-resistant NS and demonstrated rapid relief from NS (a decrease in UP to <40 mg/m²/h) in 7 (63.7 %) of 11 patients, even before the completion of LDL-A treatment [6]. The results of the current prospective study indicate that more than half of the drug-resistant NS cases are likely to be remitted by LDL-A. This response rate is slightly lower than those in previous

reports, but the level of evidence in the current study is higher.

A number of studies which reported therapeutic efficacy of LDL-A have been accumulated so far and those studies intended mostly for patients with FSGS. Although there have been several reports which showed therapeutic efficacy of LDL-A in patients with non-FSGS, most of them were case reports or case series with limited numbers of patients [12, 13]. However, in the POLARIS study, nearly half of the patients and the episodes registered in the study were non-FSGS and interestingly no significant difference of therapeutic effect was observed between FSGS and non-FSGS.

Table 4 Change of urinary protein before and after LDL-A treatment for each primary disease

| Primary diseases | n ^a | Before | After |
|--|----------------|-------------|-------------|
| Focal segmental glomerulosclerosis | 26 | 6.47 ± 2.98 | 3.26 ± 3.13 |
| Membranous nephropathy | 4 | 8.97 ± 2.29 | 6.95 ± 6.48 |
| Henoch-Schönlein purpura nephritis | 3 | 6.67 ± 4.50 | 3.15 ± 1.43 |
| Minimal change nephrotic syndrome | 2 | 1.96 ± 0.06 | 2.70 ± 3.13 |
| Renal amyloidosis | 2 | 5.45 ± 1.92 | 6.32 ± 2.52 |
| IgA nephropathy | 1 | 1.29 | 0.44 |
| Membranoproliferative glomerulonephritis | 1 | 4.60 | 1.85 |
| Crescentic glomerulonephritis | 1 | 3.81 | 0.61 |
| Lupus nephropathy | 1 | 8.79 | 0.13 |
| Hepatitis B virus-associated nephropathy | 1 | 8.90 | 3.91 |
| non-FSGS | 16 | 6.13 ± 3.41 | 3.89 ± 4.01 |

^a Episodes with not specified primary disease were excluded

From reviewing previous reports, several possible mechanisms have been proposed for the beneficial therapeutic effect of LDL-A. Firstly, direct lowering of serum lipids including LDL, oxidized LDL, and VLDL was reported to contribute to regression of glomerular injury [14, 15]. Secondly, LDL-A is known to remove pathogenic factors other than noxious lipids. LDL-A can improve hypercoagulability by reduction of coagulation factors including von Willebrand's factor and fibrinogen [16, 17], and can also improve renal hemodynamics by reducing vasoconstrictive eicosanoids such as thromboxane A2 and increasing prostaglandin I2 [9]. Thirdly, it is conceivable that LDL-A should help with improvement of therapeutic effect of antiproteinuric drugs including steroids and/or calcineurin inhibitors because bioavailability of those drugs is known to be impaired under hyperlipidemic condition [18–20]. Enrollment in the current study required a patient to be resistant to medication; and therefore, steroids and/or CsA were administered in almost all episodes concomitantly with LDL-A. In contrast, Stenvinkel et al. [21] showed that LDL-A was effective for improving the condition of NS patients with hypercholesterolemia without any additional medication. However, a clear effect of LDL-A was not observed until 6 weeks after treatment, whereas the clinical effect in our study emerged immediately after or even during LDL-A treatment. Therefore, it is likely that improvement due to the effects of concomitant steroids or CsA contributed to the short-term clinical efficacy of LDL-A.

In addition to above-mentioned mechanisms for exerting the therapeutic effect, factors that affect the clinical efficacy of LDL-A were examined based on the results obtained in this study. The level of serum total protein at pre-treatment and duration of NS before the treatment were significantly affected by the efficacy ($p = 0.049, 0.012,$

Table 5 Serum and urine parameters at pre-treatment in effective and non-effective episodes

| Clinical parameter | Unit | Effective | n | Non-effective | n | p-value |
|---|--------------------------|-----------------|----|-----------------|----|---------|
| Serum total protein (SP) | (g/dL) | 4.60 ± 0.67 | 25 | 4.20 ± 0.66 | 21 | 0.049 |
| Serum albumin (SA) | (g/dL) | 2.27 ± 0.57 | 25 | 2.03 ± 0.68 | 22 | 0.200 |
| Serum creatinine (SCr) | (mg/dL) | 1.48 ± 1.27 | 25 | 2.22 ± 1.86 | 22 | 0.117 |
| Creatinine clearance (CCr) | (mL/min) | 65.34 ± 45.13 | 13 | 71.71 ± 44.51 | 10 | 0.385 |
| estimated glomerular filtration rate (eGFR) | (mL/min/m ²) | 52.33 ± 26.12 | 25 | 44.14 ± 35.94 | 22 | 0.381 |
| Urinary protein (UP) | (g/day) | 5.56 ± 2.64 | 25 | 7.10 ± 3.15 | 22 | 0.075 |
| Triglyceride (TG) | (mg/dL) | 260.55 ± 175.58 | 22 | 265.59 ± 129.87 | 18 | 0.920 |
| Total cholesterol (TC) | (mg/dL) | 342.20 ± 99.71 | 20 | 324.00 ± 127.31 | 20 | 0.618 |
| LDL cholesterol (LDL-c) | (mg/dL) | 207.90 ± 94.14 | 20 | 203.46 ± 111.09 | 18 | 0.432 |
| HDL-cholesterol (HDL-c) | (mg/dL) | 72.08 ± 18.80 | 20 | 65.76 ± 27.44 | 14 | 0.895 |
| Fibrinogen (Fb) | (mg/dL) | 347.06 ± 109.53 | 16 | 413.34 ± 149.69 | 12 | 0.187 |
| Thrombin-antithrombin III complex (TAT) | (ng/mL) | 20.39 ± 40.84 | 12 | 8.38 ± 7.31 | 6 | 0.491 |

Table 6 Patient and episode characteristics of effective and non-effective episodes

| Patient and episode characteristics | Effective | <i>n</i> | Non-effective | <i>n</i> | <i>p</i> -value |
|--|---------------|----------|---------------|----------|--------------------|
| Age (years) | 55.57 ± 19.09 | 23 | 55.20 ± 15.36 | 20 | n.s. ^a |
| BMI | 24.01 ± 5.55 | 24 | 22.76 ± 4.15 | 16 | n.s. ^a |
| Average number of LDL-A sessions | 9.52 ± 2.55 | 25 | 9.77 ± 12.72 | 22 | n.s. ^a |
| Average frequency of LDL-A sessions (per week) | 1.92 ± 0.49 | 25 | 1.83 ± 0.47 | 20 | n.s. ^a |
| Average amount of plasma per session (L) | 3.37 ± 0.57 | 23 | 3.67 ± 0.98 | 20 | n.s. ^a |
| Duration of NS before the treatment <8 weeks | 11 (48.8 %) | 24 | 2 (5.3 %) | 19 | <0.05 ^b |
| Male | 14 (56.0 %) | 25 | 14 (63.6 %) | 22 | n.s. ^b |
| Fatigue | 17 (73.9 %) | 23 | 13 (72.2 %) | 18 | n.s. ^c |
| Edema | 23 (92.0 %) | 25 | 16 (76.2 %) | 21 | n.s. ^c |
| First time | 14 (56.0 %) | 25 | 13 (61.9 %) | 21 | n.s. ^b |
| Renal biopsy | 21 (84.0 %) | 25 | 19 (86.4 %) | 22 | n.s. ^c |
| Cyclosporine A administration | 12 (50.0 %) | 24 | 12 (54.5 %) | 22 | n.s. ^b |
| Steroid pulse therapy | 1 (4.2 %) | 24 | 3 (13.6 %) | 22 | n.s. ^c |

^a Student's t test

^b Chi-square test

^c Fisher's exact test

respectively), and also UP at pre-treatment also showed lower trend in effective episodes ($p = 0.075$) (Tables 5, 6). Not to be argued, UP and SP are distinctive indicators for severity of NS. It is suggested that patient's clinical condition has an influence on efficacy of LDL-A treatment. Hattori et al. reported that a higher selectivity index and lower degree of tubular damage were observed in pediatric patients with steroid-resistant NS who responded to LDL-A treatment compared to those who did not respond. We evaluated the duration after onset of NS dichotomized by within or more than 8 weeks. As shown in Table 7, of 13 episodes in which LDL-A was applied within 8 weeks after the onset, 11 (84.6 %) were effectively treated and recovered from nephrotic condition, whereas efficacy of the other episodes was poor (13/30, 43.3 %). Taken together, it could be considered that the less serious glomerular dysfunction and/or renal tissue damage of patients, the more likely for them to achieve effective treatment. Therefore, we suggest that LDL-A should be used immediately when a patient with NS appears not to respond to primary medication to prevent progression of renal injury.

The results of the study showed the short-term clinical efficacy of LDL-A for the treatment of drug-resistant NS in the population of patients in the POLARIS study. However, several limitations in this study need to be addressed. Most importantly, this study was conducted in an observational manner and did not intervene with concomitant therapies including medications. Therefore, the contribution of the concomitant therapies was not elucidated. In addition, the study was a single-arm study without a control group and accordingly it was difficult to directly demonstrate the efficacy of the treatment. Furthermore, the sample size was rather small to make a convincing evaluation. Although the above-mentioned limitations should be taken into consideration, this study was performed prospectively in a nationwide multicenter cohort with many more NS episodes

Table 7 Comparison of the therapeutic efficacy of LDL-A between patients who received treatment at less than ($n = 13$) and more than ($n = 30$) 8 weeks after onset of NS

| Efficacy | Period before treatment | |
|----------------------------|-------------------------|----------|
| | <8 weeks | ≥8 weeks |
| Effective (<i>n</i>) | 11 | 13 |
| Non-effective (<i>n</i>) | 2 | 17 |
| Rate | 84.6 % | 43.3 % |

The data for 4 episodes were not collected

than in previous studies and demonstrated comparable efficacy to that in the previous studies. It will be intriguing to see whether the improved clinical conditions produced by LDL-A will continue for a longer period. The final results of the POLARIS study may reveal the long-term clinical efficacy of LDL-A as an alternative therapy for drug-resistant NS.

Acknowledgments This study was supported by The Kidney Foundation, Japan and in part by a grant in relation to Progressive Renal Disease from the Ministry of Health, Labor and Welfare Research Project for Specially Selected Disease. The authors express their appreciation to all the investigators who reported clinical data in this study, including Atsushi Oyama (Nishi-Kobe Medical Center), Noriaki Henmi (Fukaya Red Cross Hospital), Noriko Mori (Shizuoka General Hospital), Osamu Nishi, (Nishi Clinic), Yasukiyo Mori (Kyoto Prefectural University of Medicine), Megumu Fukunaga (Toyonaka Municipal Hospital), Masahiko Miyamoto (Osaka Red Cross Hospital), Kenji Arizono (Kumamoto Chuo Hospital), Takako Suzuki (Moriyama Rehabilitation Hospital), Kazuhiko Hora (Hokushin General Hospital), Hiroshi Makino (Okayama University), Hideyasu Kiyomoto (Kagawa University), Yutaka Ando (Osaka Minami Medical Center), Yoshiharu Tsubakihara (Osaka General Medical Center), Kosuke Ota (Okayama Medical Center), Masamichi Fukuda (Iwakuni Medical Center Hospital), Yukiko Abe (Shin-Oura Hospital), Mitsuhiko Yoneda (Fuji Chiba Hospital), Hiroshi Ohtani (Akita Kumiai General Hospital), Tokuchihiro Sugimoto (Mitsui Memorial Hospital), Shizunori Ichida (Japanese Red Cross Nagoya Daiichi Hospital), Kentaro Wada (Nippon Kokan Fukuyama

Hospital), Rhosuke Yoshihara (Konan Kakogawa Hospital), Shoichi Fujimoto (University of Miyazaki), Morihiko Kondo (Rakuwa-kai Otowa Hospital), Takeshi Nakanishi (Hyogo College of Medicine), Kazuhiko Tsuruya (Kyusyu University), Fumiki Tanigawa (Shimonoseki Kosei Hospital), Masami Hashimoto (Onomichi General Hospital), Akiko Nakamura (Saga Prefectural Hospital Koseikan), Soshi Yorifuji (Osaka Saiseikai Nakatsu Hospital), Tamaki Sasaki (Kawasaki Medical School).

Conflict of interest None of the authors report a conflict of interest with this study.

References

- Moorhead JF, Chan MK, El-Nahas M, Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. *Lancet*. 1982;2:1309–11.
- Buemi M, Nostro L, Crasci E, Barilla A, Cosentini V, Aloisi C, Sofi T, Campo S, Frisina N. Statins in nephrotic syndrome: a new weapon against tissue injury. *Med Res Rev*. 2005;25:587–609.
- Ito S, Machida H, Inaba A, Harada T, Okuyama K, Nakamura T, Aihara Y, Yokota S. Amelioration of steroids and cyclosporine-resistant nephrotic syndrome by pravastatin. *Pediatr Nephrol*. 2007;22:603–6.
- Yokoyama S, Hayashi R, Satani M, Yamamoto A. Selective removal of low density lipoprotein by plasmapheresis in familial hypercholesterolemia. *Arteriosclerosis*. 1985;5:613–22.
- Tojo K, Sakai S, Miyahara T. Possible therapeutic application of low density lipoprotein apheresis (LDL-A) in conjunction with double filtration plasmapheresis (DFPP) in drug-resistant nephrotic syndrome due to focal glomerular sclerosis (FGS). *Jpn J Nephrol*. 1988;30:1153–60.
- Hattori M, Chikamoto H, Akioka Y, Nakakura H, Ogino D, Matsunaga A, Fukazawa A, Miyakawa S, Khono M, Kawaguchi H, Ito K. A combined low-density lipoprotein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children. *Am J Kidney Dis*. 2003;42:1121–30.
- Yokoyama K, Sakai S, Sigematsu T, Takemoto F, Hara S, Yamada A, Kawaguchi Y, Hosoya T. LDL adsorption improves the response of focal glomerulosclerosis to corticosteroid therapy. *Clin Nephrol*. 1998;50:1–7.
- Muso E, Yashiro M, Matsushima M, Yoshida H, Sawanishi K, Sasayama S. Does LDL-apheresis in steroid-resistant nephrotic syndrome affect prognosis? *Nephrol Dial Transplant*. 1994;9:257–64.
- Muso E, Mune M, Fujii Y, Imai E, Ueda N, Hatta K, Imada A, Miki S, Kuwahara T, Takamitsu Y, Takemura T, Tsubakihara Y. Low density lipoprotein apheresis therapy for steroid-resistant nephrotic syndrome. *Kansai-FGS-Apheresis Treatment (K-FLAT) Study Group. Kidney Int Suppl*. 1999;71:S122–5.
- Muso E, Mune M, Fujii Y, Imai E, Ueda N, Hatta K, Imada A, Takemura T, Miki S, Kuwahara T, Takamitsu Y, Tsubakihara Y. Significantly rapid relief from steroid-resistant nephrotic syndrome by LDL apheresis compared with steroid monotherapy. *Nephron*. 2001;89:408–15.
- Muso E, Mune M, Yorioka N, Nishizawa Y, Hirano T, Hattori M, Sugiyama S, Watanabe T, Kimura K, Yokoyama H, Sato H, Saito T. Beneficial effect of low-density lipoprotein apheresis (LDL-A) on refractory nephrotic syndrome (NS) due to focal glomerulosclerosis (FGS). *Clin Nephrol*. 2007;67:341–4.
- Kobayashi T, Ando Y, Umino T, Miyata Y, Muto S, Hironaka M, Asano Y, Kusano E. Complete remission of minimal-change nephrotic syndrome induced by apheresis monotherapy. *Clin Nephrol*. 2006;65:423–6.
- Sato Y, Tsunoda S, Nozue T, Pan Q, Wakasugi H, Yoshimura A. Low-density lipoprotein apheresis therapy for steroid- and cyclosporine-resistant idiopathic membranous nephropathy. *Intern Med*. 2012;51:2597–602.
- Schlondorff D. Cellular mechanisms of lipid injury in the glomerulus. *Am J Kidney Dis*. 1993;22:72–82.
- Diamond JR, Pesek I, McCarter MD, Kamovsky MJ. Altered functional characteristics of rat macrophages during nephrosis. Synergistic effects of hypercholesterolemia. *Am J Pathol*. 1989;135:711–8.
- Knisel W, Di Nicuolo A, Pfohl M, Muller H, Risler T, Eggstein M, Seifried E. Different effects of two methods of low-density lipoprotein apheresis on the coagulation and fibrinolytic systems. *J Intern Med*. 1993;234:479–87.
- Tasaki H, Tsuda Y, Yamashita K, Toyokawa T, Yashiro A, Osajima A, Nakashima Y, Kuroiwa A. Removal of plasma fibrinogen by LDL apheresis. *Jpn J Apheresis*. 1997;16:263.
- Petrichenko I, Daret D, Larrue J, Shakhov Y. Effect of VLDL on the inhibition of arachidonic acid transformation by dexamethasone in cultured smooth muscle cells. *Biochim Biophys Acta*. 1993;1166:183–7.
- Leon C, Jia J, Qiu G, Hill JS, Wasan KM. Modification in low-density lipoprotein receptor expression affects cyclosporin A cellular uptake and cytotoxicity. *J Pharm Sci*. 2008;97:2350–61.
- Ingulli E, Tejani A. Severe hypercholesterolemia inhibits cyclosporin A efficacy in a dose-dependent manner in children with nephrotic syndrome. *J Am Soc Nephrol*. 1992;3:254–9.
- Stenvinkel P, Alvestrand A, Angelin B, Eriksson M. LDL-apheresis in patients with nephrotic syndrome: effects on serum albumin and urinary albumin excretion. *Eur J Clin Invest*. 2000;30:866–70.

RESEARCH ARTICLE

Open Access

Clinical course after corticosteroid therapy in IgG4-related aortitis/periaortitis and periarteritis: a retrospective multicenter study

Ichiro Mizushima¹, Dai Inoue², Motohisa Yamamoto³, Kazunori Yamada¹, Takako Saeki⁴, Yoshifumi Ubara⁵, Shoko Matsui⁶, Yasufumi Masaki⁷, Takashi Wada⁸, Satomi Kasashima⁹, Kenichi Harada¹⁰, Hiroki Takahashi³, Kenji Notohara¹¹, Yasuni Nakanuma¹⁰, Hisanori Umehara⁷, Masakazu Yamagishi¹² and Mitsuhiro Kawano^{1*}

Abstract

Introduction: Immunoglobulin G4 (IgG4)-related aortitis/periaortitis and periarteritis are vascular manifestations of IgG4-related disease. In this disease, the affected aneurysmal lesion has been suspected to be at risk of rupture. In this study, we aimed to clarify the clinical course after corticosteroid therapy in IgG4-related aortitis/periaortitis and periarteritis.

Methods: We retrospectively evaluated clinical features, including laboratory data, imaging findings and the course after corticosteroid therapy, in 40 patients diagnosed with IgG4-related aortitis/periaortitis and periarteritis on the basis of periaortic/periarterial radiological findings, satisfaction of the comprehensive diagnostic criteria or each organ-specific diagnostic criteria, and exclusion of other diseases.

Results: The patients were mainly elderly, with an average age of 66.4 years and with a marked male predominance and extensive other organ involvement. Subjective symptoms were scanty, and only a small proportion had elevated serum C-reactive protein levels. The affected aorta/artery were the abdominal aortas or the iliac arteries in most cases. Thirty-six patients were treated with prednisolone, and the periaortic/periarterial lesions improved in most of them during the follow-up period. Two (50.0%) of four patients with luminal dilatation of the affected lesions before corticosteroid therapy had exacerbations of luminal dilatation after therapy, whereas none of the twenty-six patients without it had a new appearance of luminal dilatation after therapy.

Conclusions: The results of this retrospective multicenter study highlight three important points: (1) the possibility of latent existence and progression of periaortic/periarterial lesions, (2) the efficacy of corticosteroid therapy in preventing new aneurysm formation in patients without luminal dilatation of periaortic/periarterial lesions and (3) the possibility that a small proportion of patients may actually develop luminal dilatation of periaortic/periarterial lesions in IgG4-related aortitis/periaortitis and periarteritis. A larger-scale prospective study is required to confirm the efficacy and safety of corticosteroid therapy in patients with versus those without luminal dilatation and to devise a more useful and safe treatment strategy, including administration of other immunosuppressants.

* Correspondence: sk33166@gmail.com

¹Division of Rheumatology, Department of Internal Medicine, Kanazawa University Graduate School of Medicine, 13-1 Takara-machi, Kanazawa Ishikawa 920-8640, Japan

Full list of author information is available at the end of the article

Introduction

Immunoglobulin G4 (IgG4)-related disease (IgG4-RD) is a recently recognized systemic inflammatory disease with multiorgan involvement [1-3]. IgG4-RD is characterized by tumefactive lesions, a dense lymphoplasmacytic infiltration with abundant IgG4-positive plasma cells, storiform fibrosis and elevated serum IgG4 levels. Writing from a pathological viewpoint, Stone *et al.* [4] and Kasashima *et al.* [5,6] described some patients with chronic aortitis/peri-aortitis or inflammatory aortic aneurysm as also having an IgG4-related condition. Microscopically, these lesions have a predilection for the adventitia and periaortic/periarterial tissue, although they also affect the media, indicating the disease have not just a periaortitis component but also an aortitis one [4-9]. In addition, Inoue *et al.* reported characteristic computed tomography (CT) findings of 17 Japanese patients with IgG4-related periaortitis and/or periarteritis. Macroscopically, this disease represents periaortic or periarterial, circumferential or partial, thickened or masslike lesions with or without aneurysmal change [10]. Presumably, IgG4-related periaortitis and periarteritis may have some overlap with IgG4-related retroperitoneal fibrosis. Inoue *et al.* proposed that this discrimination is dependent on the predominant location of the lesions. They deemed *periaortitis* appropriate to refer to lesions with predominant periaortic and concentric involvement, whereas periureteral or plaque-like lesions should be referred to as *retroperitoneal fibrosis* [10]. In this context, the concept of IgG4-related aortitis/peri-aortitis and periarteritis (PAo/PA) has been proposed [9]. However, the clinical characteristics and course after corticosteroid therapy in patients with IgG4-related PAo/PA have not been well clarified. Moreover, although corticosteroid therapy has been suspected to increase the risk of aneurysm formation or rupture [5,8,10], the precise incidence of these complications and their timing in the clinical course have not been elucidated.

This state of affairs prompted us to undertake the present study to clarify the clinical characteristics and course after corticosteroid therapy in patients with IgG4-related PAo/PA.

Methods

Patients

From among 333 patients with IgG4-RD at Kanazawa University Hospital, Sapporo Medical University Hospital, Nagaoka Red Cross Hospital, Toranomon Hospital, Toyama University Hospital and Kanazawa Medical University Hospital between 1 January 1995 and 30 September 2013, we identified 40 with IgG4-related PAo/PA (Table 1). The diagnosis of this disease was made on the basis of the presence of consistent periaortic/periarterial radiological findings, the fulfillment of the published comprehensive diagnostic criteria (CDC

[11] or each organ-specific diagnostic criteria [12-14] and exclusion of other diseases. The diagnosis of extravascular lesions was made on the basis of physical examination, imaging findings and/or histopathological examination, in addition to exclusion of other conditions. According to the CDC, 25 patients (patients 2 through 5, 7, 8, 10, 11, 13 through 17, 19, 21 through 23, 26 through 28, 32, 34 through 36 and 38 in Table 1) were diagnosed with definite IgG4-RD, three (patients 1, 9 and 37) with probable IgG4-RD and 12 (patients 6, 12, 18, 20, 24, 25, 29 through 31, 33, 39 and 40) with possible IgG4-RD. Three (patients 6, 18 and 29) of these twelve patients fulfilled the revised diagnostic criteria for autoimmune pancreatitis (AIP) [13]. Well-experienced physicians of this disease diagnosed the remaining nine patients with IgG4-RD on the basis of a consistent clinical picture with elevated serum IgG4 concentrations and exclusion of other diseases. Twenty-nine (80.6%) of thirty-six patients who had extravascular IgG4-related organ involvement underwent biopsy of affected organs and showed histologically typical light microscopic findings [15] and copious IgG4-positive plasma cell infiltration. Histological evaluation of periaortic/periarterial lesions was performed in only one patient (patient 37) by means of incisional biopsy of the periaortic mass lesions, which did not show any vascular structures but histological findings compatible with IgG4-related retroperitoneal fibrosis. We retrospectively evaluated baseline clinical features, including subjective symptoms, laboratory data and imaging findings, in these 40 patients. Because follow-up data were absent or inadequate for seven patients (patients 1, 2, 21, 33, 37, 39 and 40), we limited the analysis of the clinical course to the remaining thirty-three patients (Figure 1). Two patients (patients 8 and 17) had been included in earlier studies ([16] and [17], respectively).

This study was approved by the Medical Ethics Committee of Kanazawa University, the institutional review board of Sapporo Medical University Hospital, the Ethics Committee of Nagaoka Red Cross Hospital, the institutional review board of Toranomon Hospital, the review board of the University of Toyama and the Research Ethics Committee of Kanazawa Medical University. Informed consent for publication of all data and samples was obtained from each patient. The research was conducted in compliance with the Declaration of Helsinki.

Imaging evaluation

All patients underwent whole-body CT examinations at the time of the initial diagnosis, and follow-up CT data were available for 33 patients, 31 of whom received corticosteroid therapy. All imaging data were reviewed by a single radiologist with extensive experience in IgG4-RD at Kanazawa University Hospital. Periaortic/periarterial lesions were described as circumferential or partial thickened wall


Table 1 Baseline characteristics of 40 patients with IgG4-related aortitis/periaortitis and periarteritis

| Patient | Follow-up (mo) | IgG (mg/dl) | IgG4 (mg/dl) | IgE (IU/ml) | CRP (mg/dl) | Location of vascular lesion | Luminal dilatation before Tx | Extravascular lesions | Symptoms | Risk factor of arteriosclerosis | Initial PSL Tx (mg/day) |
|---------|----------------|--------------------|------------------|------------------|------------------|-----------------------------|------------------------------|-----------------------|-------------------|---------------------------------|-------------------------|
| | | | | | | | | | | | |
| 1 | 204 | 1,894 | 128 | 543 | 6.2 | AA | (-) | La, Sa | abdo P, fever | (-) | 30 |
| 2 | 120 | 2,840 | 693 | 468 | 0.1 | AA | (-) | Sa | (-) | DM, Sm | 30 |
| 3 | 96 | 5,970 | 3,100 | 259 | 1.56 | AA | (-) | La, Sa, Hy, Pa | malaise | DM, HT | 40 |
| 4 | 78 | 2,140 | 557 | 266 | <0.10 | AA, IA | (+) | La, Sa | (-) | DL, Sm | 50 |
| 5 | 70 | 1,500 | 173 | 151 | 0.3 | IA, SMA | (-) | Pa, RF | abdo P | DM, HT, DL, Sm | 20 |
| 6 | 63 | 2,970 | 1,330 | 419 | <0.10 | AA | (-) | La, Sa, Pa, Ki, RF | malaise | DM, HT, DL, Sm | 40 |
| 7 | 63 | 2,130 | 715 | 253 | <0.10 | IA | (-) | La, Sa | (-) | DM, DL, Sm | 40 |
| 8 | 63 | 2,731 | 269 | 975 | 0.6 | AA | (-) | Sa, RF | (-) | DM, HT, DL, Sm | 30 |
| 9 | 57 | 1,790 ^b | 105 ^b | 212 ^b | 1.5 ^b | AA, IA | (+) | Hy, Lu, Pa, Ly | (-) | DL | 40 |
| 10 | 54 | 2,570 | 1,420 | 345 | 0.3 | AA, IA | (+) | Pa | (-) | DM, HT | 20 |
| 11 | 48 | 2,950 | 1,540 | 7.9 | <0.1 | AA | (-) | Sa, Bi, Pa, Pr | (-) | DM | 30 |
| 12 | 43 | 1,487 | 196 | 447 | 0.6 | AA, IA | (-) | RF | abdo P | DM, HT, DL, Sm | 0 |
| 13 | 37 | 2,563 | 1,330 | 283 | 0.09 | AA | (-) | Sa, Ki | pollakiuria | DL, Sm | 45 |
| 14 | 35 | 2,319 | 734 | 542 | 1.19 | TA, AA | (-) | Sa, Pa, Ki | (-) | DM, DL | 40 |
| 15 | 34 | 1,458 | 158 | 452 | 0.22 | AA | (-) | Sa, Ly | (-) | DM, HT, DL, Sm | 30 |
| 16 | 27 | 2,081 | 870 | 1,285 | 0.0 | AA, IA | (-) | Sa, RF, Pr | (-) | DM, HT | 20 |
| 17 | 27 | 1,756 | 408 | 513 | 0.2 | AA, IA | (-) | Sa, Pa, Ki | (-) | DM, HT, DL, Sm | 20 |
| 18 | 27 | 1,762 | 144 | 24 | 0.32 | AA, IA | (+) | Pa | (-) | DL, Sm | 20 |
| 19 | 25 | 2,024 | 292 | 1,400 | 0.14 | AA | (-) | Pa, RF | (-) | DM, HT, Sm | 40 |
| 20 | 24 | 2,262 | 299 | 443 | <0.05 | AA | (-) | (-) | (-) | HT | 0 |
| 21 | 24 | 2,184 | 236 | 365 | 0.3 | AA | (+) | La, Sa | fever | DM, HT, DL | 30 |
| 22 | 22 | 3,484 | 1,896 | 247 | 0.0 | AA | (-) | La, Sa, Pa, Ki, Ly | (-) | Sm | 35 |
| 23 | 15 | 4,171 | 2,120 | <20 | 0.32 | AA, IA | (-) | La, Sa, Ki | (-) | DM, HT, Sm | 40 |
| 24 | 13 | 1,837 | 261 | 687 | 0.06 | IA | (-) | RF | (-) | HT, DL | 30 |
| 25 | 13 | 1,454 | 196 | 350 | 0.13 | AA, IA | (-) | (-) | abdo P | Sm | 15 |
| 26 | 10 | 2,213 | 455 | NA | 0.56 | AA, IA | (-) | Sa, Ki | arthralgia | HT, DL, Sm | 40 |
| 27 | 10 | 3,120 | 1,020 | 1,760 | 1.5 | AA, IA, IMA | (-) | La, Sa | hoarseness, fever | Sm | 30 |
| 28 | 9 | 2,936 | 1,070 | 17 | 0.0 | TA, AA, IA | (-) | La, Sa, Pa, Ki | thirst | DM, DL, Sm | 40 |
| 29 | 9 | 10,121 | 2,500 | <20 | 0.37 | IA | (+) | Pa, Ki, Ly | malaise | DM | 50 |
| 30 | 9 | 1,200 | 147 | NA | 2.94 | AA, IA | (-) | (-) | fever, malaise | DM, HT | 30 |

Table 1 Baseline characteristics of 40 patients with IgG4-related aortitis/periaortitis and periarteritis (Continued)

| | | | | | | | | | | | |
|----|---|-------|-------|-----|------|--------|-----|------------------------|-----------------|------------|----|
| 31 | 8 | 1,475 | 210 | 111 | 0.3 | IA | (-) | Sa | (-) | (-) | 40 |
| 32 | 4 | 2,938 | 1,520 | 48 | 0.1 | AA | (-) | La, Sa, Ki, RF | (-) | Sm | 30 |
| 33 | 4 | 1,463 | 672 | 216 | 0.13 | AA | (-) | Sa, Pl, Ca | (-) | Sm | 0 |
| 34 | 3 | 2,439 | 782 | 703 | 0.2 | AA, IA | (-) | La, Ki, RF | (-) | DM, DL, Sm | 20 |
| 35 | 3 | 2,244 | 503 | 311 | 0.0 | AA, IA | (-) | Ki | edema | (-) | 30 |
| 36 | 2 | 1,950 | 711 | 737 | 0.0 | AA | (-) | La, Sa, Lu, Ki | (-) | Sm | 35 |
| 37 | 2 | 1,328 | 106 | 19 | 0.28 | AA, IA | (+) | RF | (-) | DL | 0 |
| 38 | 1 | 4,420 | 2,680 | 174 | 0.1 | IA | (-) | La, Sa, Bi, Pa, Ki, Ne | diarrhea | Sm | 50 |
| 39 | 1 | 2,276 | 835 | <20 | 0.91 | IA | (-) | Sa | (-) | HT | 15 |
| 40 | 1 | 1,600 | 206 | 212 | 0.38 | AA | (-) | (-) | abdo P, malaise | Sm | 30 |

AA, Abdominal aorta; *abdo*, Abdominal; *Bi*, Bile tract; *Ca*, Pericarditis; *CRP*, C-reactive protein; *DL*, Dyslipidemia; *DM*, Diabetes mellitus; *F*, Female; *HT*, Hypertension; *Hy*, Hypophysitis; *IA*, Iliac artery; *IgE*, Serum immunoglobulin E at diagnosis; *IgG*, Serum immunoglobulin G at diagnosis; *IgG4*, Serum immunoglobulin G4 at diagnosis; *IMA*, Inferior mesenteric artery; *Ki*, IgG4-related kidney disease; *La*, Lacrimal gland, *Lu*, Lung; *Ly*, Lymph node; *M*, Male; *Mo*, month; *NA*, Not available; *Ne*, Nerve; *P*, Pain; *Pa*, Pancreas; *Pl*, Pleuritis; *Pr*, Prostate; *PSL*, Prednisolone; *RF*, Retroperitoneal fibrosis; *Sa*, Salivary gland; *Sm*, Past or current smoking; *SMA*, Superior mesenteric artery; *TA*, Thoracic aorta; *Tx*, Treatment. ^aValue under corticosteroid therapy.



of the affected aortas/arteries with homogeneous enhancement visualized by contrast-enhanced CT. At the time of diagnosis, we also evaluated the findings of 2-¹⁸F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (FDG-PET/CT) for 20 patients and of gallium scintigraphy for 12 patients.

At the time of initial diagnostic CT imaging, after noting the affected site of aortas/arteries and extravascular lesions, we measured the maximum vascular wall thickness and diameter of the lumen in both affected and adjacent sites in each lesion. These two values were then longitudinally evaluated in the 33 patients whose follow-up imaging and clinical course information were available.

Improvement and relapse of periaortic/periarterial lesions during the clinical course were defined as decrease and reincrease of vascular wall thickness, respectively, at the same site as the maximum vascular wall thickness measured at the time of initial diagnosis. Luminal dilatation of periaortic/periarterial lesions was defined as being present when the luminal diameter of the affected site was more than 3 mm larger than that of adjacent normal sites. Exacerbation of luminal dilatation was defined as being present when more than 5-mm expansion of the luminal diameter was observed at the same site as the luminal dilatation detected at the time of initial diagnosis.

Statistical analysis

Statistical analysis was performed using SPSS version 19 software (IBM SPSS, Chicago, IL, USA). The significance of differences between groups was determined using Mann-Whitney *U* test or Wilcoxon signed-rank test, and the significance of differences in frequencies was analyzed with Fisher's exact probability test. Data are presented as means ± SD. Significant differences were defined as *P* < 0.05.

Results

Baseline characteristics

The baseline clinical characteristics of 40 patients are shown in Table 1. Our patient group was composed of 37 men and 3 women with an average age of 66.4 ± 7.1 years (age range, 44 to 75). One patient (patient 9 in Table 1) had been treated with prednisolone (PSL) at a dose of 5.0 mg/day for type 1 AIP. None of the other 39 patients had been treated with any immunosuppressants, including corticosteroids, before their diagnosis. Thirty-six patients (90.0%) had more than one IgG4-related extravascular lesion (average, 2.3 ± 1.5 organs; range, 0 to 6 organs). Involvement of the salivary gland was observed in 25 patients (62.5%), lacrimal gland in 14 (35.0%), pancreas in 14 (35.0%), kidney in 13 (32.5%), retroperitoneum in 13

(32.5%), prostate in 6 (15.0%), lung in 3 (7.5%) and hepatobiliary tract and hypophysis in 2 each (5.0%). The frequency of subjective symptoms was low (fever, 10.0%; abdominal pain, 12.5%; general malaise, 12.5%). Moreover, five of seven patients with luminal dilatation of the affected lesions at the time of diagnosis complained of no subjective symptoms. With regard to the major risk factors of atherosclerosis, diabetes mellitus (DM) was present at the time of diagnosis in 20 patients (50.0%), hypertension (HT) in 17 (42.5%), dyslipidemia (DL) in 18 (45.0%), current smoking in 9 (22.5%) and past smoking in 15 (37.5%). The mean follow-up period of all 40 patients after diagnosis was 33.9 ± 39.8 months (range, 1 to 204 months).

At diagnosis, 37 (92.5%) of 40 patients showed elevated serum IgG4 levels exceeding 135 mg/dl (average, 815 ± 771 mg/dl; range, 105 to 3,100 mg/dl). Thirty-one (77.5%) of forty patients showed elevated serum IgG levels (average, $2,551 \pm 1,543$ mg/dl; range, 1,200 to 10,121 mg/dl; normal range, 870 to 1,700 mg/dl). Twenty-three (60.5%) of thirty-eight evaluated patients showed elevated serum IgE levels (average, 403 ± 398 IU/ml; range, 7.9 to 1,760 IU/ml; normal range, <250 IU/ml). Although none of the patients had leukocytosis, 16 (41.0%) of 39 evaluated patients had eosinophilia (eosinophils >5%). Six (15.4%) of thirty-nine evaluated patients had hypocomplementemia. Antinuclear antibodies were positive in 16 (40.0%) of 40 patients and the rheumatoid factor in only 3 (8.1%) of 37 evaluated patients. Myeloperoxidase antineutrophil cytoplasmic antibodies (ANCA) and proteinase 3 ANCA were not observed in any of the evaluated patients (21 and 14 patients, respectively). Only six (15.0%) of forty patients had elevated serum C-reactive protein (CRP) level (CRP >1 mg/dl).

Treatment

The respective attending physicians decided the indications for treatment and the treatment regimen. Thirty-six of forty patients were treated with PSL at an average initial dose of 32.6 ± 9.7 mg/day (range, 15 to 50 mg/day) for the lesions associated with IgG4-RD. Only one patient (patient 1 in Table 1) received cyclophosphamide in addition to PSL. Endovascular aortic repair (EVAR) was performed for the periaortic lesions with marked luminal dilatation before corticosteroid therapy in one patient (patient 18) to prevent rupture. We excluded five patients (patients 1, 2, 21, 39 and 40) from the analysis of the clinical course because their follow-up imaging data were not available. During the clinical course of the other 31 patients, the initial PSL dose was generally continued until 2 to 4 weeks after the start of therapy and then gradually tapered. The PSL dose was tapered to 5 to 10 mg/day by 12 months in 18 (94.7%) of 19 patients whose follow-up period was more than 12 months. The

average PSL dose at the last review was 10.0 ± 9.2 mg/day. Because one patient (patient 12) showed strong positivity in the tuberculin skin test and interferon γ release assays, he was treated with antituberculosis therapy only. The other three patients (patients 20, 33 and 37) were observed without any treatment (Figure 1).

Radiological findings at diagnosis

CT images revealed thickened lesions surrounding the aorta/artery in all patients. The affected aorta/artery data were for two thoracic aortas (Figure 2A), thirty-three abdominal aortas (Figure 2C), twenty-three iliac arteries (Figure 2E), one superior mesenteric artery (Figure 2G) and one inferior mesenteric artery. All 33 abdominal aortic lesions affected the infrarenal abdominal aorta, and only 6 lesions also affected the suprarenal abdominal aorta. CT also revealed typical extravascular lesions, mainly in the salivary glands, lacrimal glands, pancreas and kidney. Sixteen of twenty patients who underwent FDG-PET/CT, and only four of twelve patients who underwent gallium scintigraphy, showed significant uptake of the periaortic/periarterial lesions detected by CT.

Changes in radiological findings of periaortic/periarterial lesions after corticosteroid therapy

After corticosteroid therapy, reduction in the thickness of the periaortic/periarterial lesions was observed during an average follow-up period of 30.1 ± 26.2 months (range, 1 to 96 months) in 30 (96.8%) of 31 patients whose clinical course was analyzed (Figure 2), although 1 patient (patient 9 in Table 1) experienced relapse during PSL tapering at a dose of 7.0 mg/day. The average vascular wall thickness of the 34 periaortic/periarterial lesions of 31 patients at the time of diagnosis (7.1 ± 3.0 mm; range, 3 to 18 mm) significantly decreased after corticosteroid therapy (2.7 ± 2.0 mm; range, 1 to 9 mm) (Figure 2I). Generally, obvious radiographic improvement of more than 50% reduction in thickness was observed by 2 months after the start of therapy, after which point some patients showed further improvement and others showed almost no change (Figure 3). Eighteen of the thirty-four lesions had almost completely disappeared by the time of the last review. The rate of improvement, relapse or complete disappearance of the perivascular lesions did not differ significantly between the patients with multiple versus single vascular involvement, between those with versus without a specific other organ involvement such as AIP or between the presence or absence of any of the specific risk factors of atherosclerosis.

Luminal changes after corticosteroid therapy

Of the 31 patients whose clinical course was analyzed after corticosteroid therapy, 5 (patients 4, 9, 10, 18 and 29 in Table 1) had luminal dilatation of the periaortic/




Figure 2 Contrast-enhanced computed tomography findings of periaortic/periarterial lesions and changes after corticosteroid therapy. A thoracic aortic lesion (A) had slightly improved 1 month after corticosteroid therapy (B), an abdominal aortic lesion (C) and an iliac arterial lesion (E) had almost disappeared 10 months after therapy (D and F, respectively) and a superior mesenteric arterial lesion (G) showed fair improvement 2 months after therapy (H). Significant pre- to posttherapy decreases in maximum wall thickness of periaortic/periarterial lesions were observed (I). Tx, Treatment.




Figure 3 Changes in maximum vascular wall thickness of periaortic/periarterial lesions after the start of corticosteroid therapy. Data for patients who underwent follow-up computed tomography within 2 months after the start of therapy are shown.

periarterial lesions at the time of the initial CT (Figures 4A, 4C and 4E) and three (patients 10, 18 and 29) of them were diagnosed as having inflammatory aneurysm. One (patient 18) of them was treated with EVAR and PSL administration and did not have exacerbation of the luminal dilatation during the follow-up. The other four patients received PSL administration alone, in two (patients 9 and 10) of whom (50%) the luminal dilatation was exacerbated 28 and 46 months after the start of therapy, respectively (Figures 4B, 4D, 4F and 4G). Throughout the clinical course, patient 9 did not have hypertension and patient 10 received antihypertensive agents, which achieved good blood pressure control (below 140/90 mmHg). The luminal diameter was stable after corticosteroid therapy in the 26 patients without luminal dilatation at diagnosis (Figure 4H).

Outcome of patients without corticosteroid therapy

Four patients (patients 12, 20, 33 and 37 in Table 1) did not receive corticosteroid therapy. One patient (patient 12) treated with antituberculosis therapy had gradual improvement of serum IgG4 level, periaortic/periarterial lesions and retroperitoneal fibrosis. In another untreated patient (patient 20), periaortic/periarterial lesion showed no change during the 24-month follow-up period. No new appearance of luminal dilatation was observed in these two patients. Because follow-up imaging data of the other patients were lacking, we excluded them from the analysis of the clinical course.

Discussion

We analyzed the clinical course after corticosteroid therapy in patients with IgG4-related PAo/PA. To our knowledge, this study is the largest to evaluate corticosteroid safety and effectiveness in preventing new aneurysm formation in patients without luminal dilatation of periaortic/periarterial lesions, as well as the risk for exacerbation of luminal dilatation of such lesions in patients with it before therapy.

Biopsy of periaortic/periarterial lesions may cause massive hemorrhage. In our study, we could not perform histopathological examinations of these lesions, with the single exception of patient 37, whose specimens obtained by incisional biopsy of periaortic mass lesions showed only findings compatible with IgG4-related retroperitoneal fibrosis because of a lack of vasculature structures. To compensate for this difficulty, the presence of IgG4-related extravascular lesions, in addition to serological and typical radiological findings, was helpful in making a diagnosis of IgG4-related PAo/PA.

In contrast to our present study, the frequency of extravascular lesions was low in several previous studies. In those studies, periaortic/periarterial lesions were at an advanced stage with frequent aneurysmal formation, and the diagnosis was based mainly on the histopathological findings of the periaortic/periarterial lesions themselves because surgical treatment was selected [4,6,7,18,19]. In contrast, our cases seem to have been at an earlier stage, attributable to the fact that the identification of extravascular lesions




Figure 4 Exacerbation of luminal dilatation after corticosteroid therapy. Luminal dilatation (A and C, patient 10 in Table 1; E, patient 9) of the periaortic/periarterial lesions at the time of diagnosis was exacerbated after corticosteroid therapy (B, D and F, respectively). Red lines in each of the three paired images (A and B, C and D, and E and F, respectively) have the same length. Of five lesions from four patients with luminal dilatation, three lesions from two patients (red and yellow) in the maximum luminal diameter increased (G), whereas no obvious increase was observed in the 28 lesions of the 26 patients without luminal dilatation (H). Tx, Treatment.

and the recent greater awareness of these lesions facilitated the making of an early diagnosis.

Accordingly, in vasculature-restricted cases, the correct diagnosis of IgG4-RD is much more difficult to make. To diagnose such patients early, the indications and accuracy of CT-guided biopsy of periaortic/periarterial lesions should be investigated, the risks and benefits of a diagnostic trial of corticosteroid therapy should be evaluated and a search for other valuable and less-invasive diagnostic markers should be undertaken. In such cases, it is of great importance to exclude other differential diagnoses, such as malignancy, infections, autoimmune disease and drug reactions, which can mimic IgG4-related PAo/PA [20,21].

A definitive therapeutic strategy for IgG4-related PAo/PA has not been established, and to date indications for treatment and the type of treatment regimen have been decided by the respective attending physician. In type 1 AIP (IgG4-related pancreatitis), the pancreatic manifestation of IgG4-RD, consensus guidelines for treatment, which are based on copious clinical experience [22], have been available since 2010 [23]. In AIP patients, corticosteroid administration should be employed for patients with symptoms such as obstructive jaundice and abdominal and back pain. The initial oral PSL dose of 0.6 mg/kg/day, continuation of the initial dose for 2 to 4 weeks and tapering by 5 mg every 1 to 2 weeks to a maintenance dose (2.5 to 5 mg/day) over a period of 2 to 3 months are recommended. In our study, corticosteroid therapy was started at an initial PSL dose of less than 30 mg/day for eight patients, 30 to 40 mg/day for twenty-four patients and over 40 mg/day for four patients. In most of the patients whose follow-up period was more than 12 months, the PSL dose was tapered to 5 to 10 mg/day by 12 months. In this way, the initial therapy generally following the guidelines of AIP and maintenance therapy with relatively slow tapering were performed in our study, with good efficacy attained on the whole.

The results of this study suggest that luminal dilatation of affected lesions may actually occur during corticosteroid therapy in patients with IgG4-related PAo/PA. In past studies [5,8,10], it was speculated that corticosteroid and other immunosuppressive therapies might increase the risk of aneurysm rupture. Actually, an IgG4-RD patient with multiple aneurysms who died of aneurysm rupture after high-dose corticosteroid therapy has been reported [24]. In our present study, of 31 patients treated with corticosteroid, exacerbation of luminal dilatation were observed in only 2 who had already had it before therapy. Because blood pressure was maintained below 140/90 mmHg in these patients throughout their clinical course, hemodynamics seemed not to have influenced the exacerbation of luminal dilatation in any obvious fashion. In contrast, no patient without luminal dilatation showed a new appearance of it after therapy. These results suggest that

more careful observation during corticosteroid therapy may be necessary to detect further luminal dilatation early in IgG4-related PAo/PA patients with preexisting luminal dilatation. However, because no patient with luminal dilatation and only one patient without luminal dilatation were observed without corticosteroid therapy, the natural course of the disease or of preexisting dilatation was not clarified. Moreover, the small number of patients with luminal dilatation precluded statistical analysis of the influence of independent risk factors on the luminal dilatation in IgG4-related PAo/PA. Therefore, whether preexisting luminal dilatation, corticosteroid therapy or some other factor is an independent risk factor for the aneurysm formation or exacerbation in IgG4-related PAo/PA patients will have to be clarified through multivariate analysis in a larger prospective study.

This study's results appear to support the contention that corticosteroid therapy can prevent new appearance of luminal dilatation in patients without it before therapy. In two case reports of IgG4-related aortitis/periaortitis patients with ruptured aortic aneurysms [25,26], immunosuppressive agents, including corticosteroids, had not been administered before aneurysm rupture. These case reports suggest that IgG4-related PAo/PA is itself a risk for aneurysm formation resulting in rupture when the lesions are left untreated. However, considering that no patient without luminal dilatation showed new appearance of it after therapy in our study, it is reasonable to surmise that corticosteroid therapy improves periaortic/periarterial lesions and prevents aneurysm formation at the affected site.

Therapeutic alternatives to corticosteroids have not been well-established in IgG4-RD. In some case reports and small case series, some oral immunosuppressive drugs, including azathioprine [27], methotrexate [28] and mycophenolate mofetil [29], have been reported to be effective. In addition, good effectiveness of rituximab, which eliminates B cells by binding the cell-surface marker CD20, has been described [30,31]. However, the efficacy of these drugs remains to be evaluated with regard to their effectiveness for periaortic/periarterial lesions and their influence on luminal dilatation in IgG4-related PAo/PA.

This study has a few limitations. First, the treatment regimen and follow-up protocols were inconsistent between patients because of its retrospective and multi-institutional nature. Second, although this study included more patients than past ones, the number of patients with luminal dilatation at the time of diagnosis was small. Third, the association between histopathological findings and clinical features could not be evaluated, because biopsy specimens for histopathological analysis of the periaortic/periarterial lesions could not be procured. Fourth, no patient with luminal dilatation at the time of diagnosis was observed without corticosteroid therapy.

Conclusions

The results of our study show the possibility of latent existence and progression of periaortic/periarterial lesions, the efficacy of corticosteroid therapy in preventing new aneurysm formation in patients without luminal dilatation of periaortic/periarterial lesions, and the possibility that a small proportion of patients may actually experience luminal dilatation of periaortic/periarterial lesions in IgG4-related PAO/PA. To confirm the efficacy and safety of corticosteroid therapy in patients with versus without luminal dilatation, and to devise a more useful and safe treatment strategy, including administration of other immunosuppressants, a larger-scale prospective study is required.

Abbreviations

AIP: Autoimmune pancreatitis; CDC: Comprehensive diagnostic criteria; CRP: C-reactive protein; CT: Computed tomography; EVAR: Endovascular aortic repair; FDG-PET/CT: 2-[¹⁸F]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography; IgG4: Immunoglobulin G4; IgG4-RD: Immunoglobulin G4 (IgG4)-related disease; IgG4-related PAO/PA: IgG4-related aortitis/periarteritis and periarteritis; PSL: Prednisolone.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

IM and MK were responsible for study conception and design, data collection, data analysis and manuscript writing. DJ, MoY, KY, TS, YU, SM, YM and TW were responsible for data collection, data analysis and critical revision of the manuscript. SK, KH, KN and YN were responsible for study conception and design and critical revision of the manuscript. HT and HU were responsible for data collection, data analysis and critical revision of the manuscript. MaY was responsible for study conception and design, data collection, data analysis and critical revision of the manuscript. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Acknowledgments

We thank John Gelblum for his critical reading of the manuscript and Akihiro Sagara for his referral of a patient. This work was supported by Health and Labour Sciences Research grants for the Study of Intractable Diseases from the Ministry of Health, Labour and Welfare, Japan.

Author details

¹Division of Rheumatology, Department of Internal Medicine, Kanazawa University Graduate School of Medicine, 13-1 Takara-machi, Kanazawa Ishikawa 920-8640, Japan. ²Department of Radiology, Kanazawa University Graduate School of Medical Science, 13-1 Takara-machi, Kanazawa, Ishikawa 920-8640, Japan. ³The First Department of Internal Medicine, Sapporo Medical University, South 1, West 16, Chuo-ku, Sapporo, Hokkaido 060-8543, Japan. ⁴Department of Internal Medicine, Nagaoka Red Cross Hospital, 2-297-1 Senshu, Nagaoka, Niigata 940-2085, Japan. ⁵Nephrology Center, Toranomon Hospital, 1-3-1 Kajigaya, Takatsu, Kawasaki, Kanagawa 212-0015, Japan. ⁶Health Administration Center, Sugitani Campus, University of Toyama, 2630 Sugitani, Toyama-shi, Toyama 930-0194, Japan. ⁷Department of Hematology and Immunology, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Kahokugun, Ishikawa 920-0293, Japan. ⁸Division of Nephrology, Department of Laboratory Medicine, Kanazawa University, 13-1 Takara-machi, Kanazawa, Ishikawa 920-8640, Japan. ⁹Department of Pathology and Clinical Laboratory, National Hospital Organization, Kanazawa Medical Center, 1-1 Shimoisibikimachi, Kanazawa, Ishikawa 920-8650, Japan. ¹⁰Department of Human Pathology, Kanazawa University Graduate School of Medicine, 13-1 Takara-machi, Kanazawa, Ishikawa 920-8640, Japan. ¹¹Department of Pathology, Kurashiki Central Hospital, Miwa, Kurashiki, Okayama 710-8602, Japan. ¹²Division of Cardiology, Department of Internal Medicine, Kanazawa University Graduate School of Medicine, 13-1 Takara-machi, Kanazawa, Ishikawa 920-8640, Japan.

Received: 30 January 2014 Accepted: 8 July 2014

Published: 23 July 2014

References

- Masaki Y, Dong L, Kurose N, Kitagawa K, Morikawa Y, Yamamoto M, Takahashi H, Shinomura Y, Imai K, Saeki T, Azumi A, Nakada S, Sugiyama E, Matsui S, Origuchi T, Nishiyama S, Nishimori I, Nojima T, Yamada K, Kawano M, Zen Y, Kaneko M, Miyazaki K, Tsubota K, Eguchi K, Tomoda K, Sawaki T, Kawanami T, Tanaka M, Fukushima T, et al: **Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders.** *Ann Rheum Dis* 2009, **68**:1310–1315.
- Stone JH, Zen Y, Deshpande V: **IgG4-related disease.** *N Engl J Med* 2012, **366**:539–551.
- Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T, Matsui S, Sumida T, Mimori T, Tanaka Y, Tsubota K, Yoshino T, Kawa S, Suzuki R, Takegami T, Tomosugi N, Kurose N, Ishigaki Y, Azumi A, Kojima M, Nakamura S, Inoue D: **A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details.** *Mod Rheumatol* 2012, **22**:1–14.
- Stone JH, Khosroshahi A, Deshpande V, Stone JR: **IgG4-related systemic disease accounts for a significant proportion of thoracic lymphoplasmacytic aortitis cases.** *Arthritis Care Res* 2010, **62**:316–322.
- Kasashima S, Zen Y: **IgG4-related inflammatory abdominal aortic aneurysm.** *Curr Opin Rheumatol* 2011, **23**:18–23.
- Kasashima S, Kawashima A, Endo M, Matsumoto Y, Kasashima F, Zen Y, Nakanuma Y: **A clinicopathologic study of immunoglobulin G4-related disease of the femoral and popliteal arteries in the spectrum of immunoglobulin G4-related periarteritis.** *J Vasc Surg* 2013, **57**:816–822.
- Stone JR: **Aortitis, periarteritis, and retroperitoneal fibrosis, as manifestations of IgG4-related systemic disease.** *Curr Opin Rheumatol* 2011, **23**:88–94.
- Zen Y, Kasashima S, Inoue D: **Retroperitoneal and aortic manifestations of immunoglobulin G4-related disease.** *Semin Diagn Pathol* 2012, **29**:212–218.
- Stone JH, Khosroshahi A, Deshpande V, Chan JK, Heathcote JG, Aalberse R, Azumi A, Bloch DB, Brugge WR, Carruthers MN, Cheuk W, Cornell L, Castillo CF, Ferry JA, Forcione D, Klöppel G, Hamilos DL, Kamisawa T, Kasashima S, Kawa S, Kawano M, Masaki Y, Notohara K, Okazaki K, Ryu JK, Saeki T, Sahani D, Sato Y, Smyrk T, Stone JR, et al: **Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations.** *Arthritis Rheum* 2012, **64**:3061–3067.
- Inoue D, Zen Y, Abo H, Gabata T, Demachi H, Yoshikawa J, Miyayama S, Nakanuma Y, Matsui O: **Immunoglobulin G4-related periarteritis and periarteritis: CT findings in 17 patients.** *Radiology* 2011, **261**:625–633.
- Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T, Matsui S, Yoshino T, Nakamura S, Kawa S, Hamano H, Kamisawa T, Shimosegawa T, Shimatsu A, Nakamura S, Ito T, Notohara K, Sumida T, Tanaka Y, Mimori T, Chiba T, Mishima M, Hibi T, Tsubouchi H, Inui K, Ohara H: **Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011.** *Mod Rheumatol* 2012, **22**:21–30.
- Masaki Y, Sugai S, Umehara H: **IgG4-related diseases including Mikulicz's disease and sclerosing pancreatitis: diagnostic insights.** *J Rheum* 2010, **37**:1380–1385.
- Okazaki K, Kawa S, Kamisawa T, Shimosegawa T, Tanaka M: **Japanese consensus guidelines for management of autoimmune pancreatitis: I. Concept and diagnosis of autoimmune pancreatitis.** *J Gastroenterol* 2010, **45**:249–265.
- Kawano M, Saeki T, Nakashima H, Nishi S, Yamaguchi Y, Hisano S, Yamanaka N, Inoue D, Yamamoto M, Takahashi H, Nomura H, Taguchi T, Umehara H, Makino H, Saito T: **Proposal for diagnostic criteria for IgG4-related kidney disease.** *Clin Exp Nephrol* 2011, **15**:615–626.
- Deshpande V, Zen Y, Chan JK, Yi EE, Sato Y, Yoshino T, Klöppel G, Heathcote JG, Khosroshahi A, Ferry JA, Aalberse RC, Bloch DB, Brugge WR, Bateman AC, Carruthers MN, Chari ST, Cheuk W, Cornell LD, Fernandez-Dei Castillo C, Forcione DG, Hamilos DL, Kamisawa T, Kasashima S, Kawa S, Kawano M, Lauwers GY, Masaki Y, Nakanuma Y, Notohara K, Okazaki K, et al: **Consensus statement on the pathology of IgG4-related disease.** *Mod Pathol* 2012, **25**:1181–1192.
- Matsui S, Taki H, Shinoda K, Suzuki K, Hayashi R, Tobe K, Tokimitsu Y, Ishida M, Fushiki H, Seto H, Fukuoka J, Ishizawa S: **Respiratory involvement in IgG4-related Mikulicz's disease.** *Mod Rheumatol* 2012, **22**:31–39.
- Saeki T, Kawano M, Mizushima I, Yamamoto M, Wada Y, Nakashima H, Homma N, Tsubata Y, Takahashi H, Ito T, Yamazaki H, Saito T, Narita I: **The**

- clinical course of patients with IgG4-related kidney disease. *Kidney Int* 2013, **84**:826–833.
18. Kasashima S, Zen Y, Kawashima A, Endo M, Matsumoto Y, Kasashima F: A new clinicopathological entity of IgG4-related inflammatory abdominal aortic aneurysm. *J Vasc Surg* 2009, **49**:1264–1271.
 19. Kasashima S, Zen Y, Kawashima A, Endo M, Matsumoto Y, Kasashima F, Ohtake H, Nakanuma Y: A clinicopathological study of IgG4-related sclerosing disease of the thoracic aorta. *J Vasc Surg* 2010, **52**:1587–1595.
 20. Palmisano A, Vaglio A: Chronic periaortitis: a fibro-inflammatory disorder. *Best Pract Res Clin Rheumatol* 2009, **23**:339–353.
 21. Siddiquee Z, Zane NA, Smith RN, Stone JR: Dense IgG4 plasma cell infiltrates associated with chronic infectious aortitis: implications for the diagnosis of IgG4-related disease. *Cardiovasc Pathol* 2012, **21**:470–475.
 22. Kamisawa T, Shimosegawa T, Okazaki K, Nishino T, Watanabe H, Kanno A, Okumura F, Nishikawa T, Kobayashi K, Ichiya T, Takatori H, Yamakita K, Kubota K, Hamano H, Okamura K, Hirano K, Ito T, Ko SB, Omata M: Standard steroid treatment for autoimmune pancreatitis. *Gut* 2009, **58**:1504–1507.
 23. Kamisawa T, Okazaki K, Kawa S, Shimosegawa T, Tanaka M: Japanese consensus guidelines for management of autoimmune pancreatitis: III. Treatment and prognosis of AIP. *J Gastroenterol* 2010, **45**:471–477.
 24. Tajima M, Hiroi Y, Takazawa Y, Muraoka H, Iwata H, Yamashita H, Hirata Y, Nagai R: Immunoglobulin G4-related multiple systemic aneurysms and splenic aneurysm rupture during steroid therapy. *Hum Pathol* 2014, **45**:175–179.
 25. Qian Q, Kashani KB, Miller DV: Ruptured abdominal aortic aneurysm related to IgG4 periaortitis. *N Engl J Med* 2009, **361**:1121–1123.
 26. Trinidad-Hernandez M, Duncan AA: Contained ruptured paravisceral aortic aneurysm related to immunoglobulin G4 aortitis. *Ann Vasc Surg* 2012, **26**:108.e1–e4.
 27. Naitoh I, Nakazawa T, Ohara H, Sano H, Ando T, Hayashi K, Tanaka H, Okumura F, Miyabe K, Yoshida M, Takahashi S, Joh T: Autoimmune pancreatitis associated with various extrapancreatic lesions during a long-term clinical course successfully treated with azathioprine and corticosteroid maintenance therapy. *Intern Med* 2009, **48**:2003–2007.
 28. Hyun JW, Kim SH, Yoo H, Hong EK, Huh SY, Kim HJ: Steroid-resistant relapsing IgG4-related pachymeningitis treated with methotrexate. *JAMA Neurol* 2014, **71**:222–225.
 29. Moss HE, Mejico LJ, de la Roza G, Coyne TM, Galetta SL, Liu GT: IgG4-related inflammatory pseudotumor of the central nervous system responsive to mycophenolate mofetil. *J Neurol Sci* 2012, **318**:31–35.
 30. Khosroshahi A, Bloch DB, Deshpande V, Stone JH: Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. *Arthritis Rheum* 2010, **62**:1755–1762.
 31. Khosroshahi A, Carruthers MN, Deshpande V, Unizony S, Bloch DB, Stone JH: Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients. *Medicine (Baltimore)* 2012, **91**:57–66.

doi:10.1186/ar4671

Cite this article as: Mizushima *et al.*: Clinical course after corticosteroid therapy in IgG4-related aortitis/periaortitis and periarteritis: a retrospective multicenter study. *Arthritis Research & Therapy* 2014 **16**:R156.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit



Clinical impact of albuminuria and glomerular filtration rate on renal and cardiovascular events, and all-cause mortality in Japanese patients with type 2 diabetes

Takashi Wada · Masakazu Haneda · Kengo Furuichi · Tetsuya Babazono · Hiroki Yokoyama · Kunitoshi Iseki · Shin-ichi Araki · Toshiharu Ninomiya · Shigeko Hara · Yoshiki Suzuki · Masayuki Iwano · Eiji Kusano · Tatsumi Moriya · Hiroaki Satoh · Hiroyuki Nakamura · Miho Shimizu · Tadashi Toyama · Akinori Hara · Hirofumi Makino · The Research Group of Diabetic Nephropathy, Ministry of Health, Labour, and Welfare of Japan

Received: 3 August 2013 / Accepted: 21 September 2013 / Published online: 17 October 2013
© Japanese Society of Nephrology 2013

Abstract

Background The number of patients suffering from diabetic nephropathy resulting in end-stage kidney disease is increasing worldwide. In clinical settings, there are limited data regarding the impact of the urinary albumin-to-creatinine ratio (UACR) and reduced estimated glomerular filtration rate (eGFR) on renal and cardiovascular outcomes and all-cause mortality.

Methods We performed a historical cohort study of 4328 Japanese participants with type 2 diabetes from 10 centers. Risks for renal events (requirement for dialysis or

transplantation, or half reduction in eGFR), cardiovascular events (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke), and all-cause mortality were assessed according to UACR and eGFR levels.

Results During follow-up (median 7.0 years, interquartile range 3.0–8.0 years), 419 renal events, 605 cardiovascular events and 236 deaths occurred. The UACR levels increased the risk and the adjusted hazard ratios for these three events. In addition to the effects of UACR levels, eGFR stages significantly increased the adjusted hazard ratios for renal events and all-cause mortality, especially in

T. Wada · K. Furuichi · M. Shimizu · T. Toyama · A. Hara
Division of Nephrology, Kanazawa University Hospital,
Kanazawa, Japan

T. Wada (✉)
Division of Nephrology, Department of Laboratory Medicine,
Institute of Medical, Pharmaceutical and Health Sciences,
Faculty of Medicine, Kanazawa University, Kanazawa,
13-1 Takara-machi, Kanazawa 920-8641, Japan
e-mail: twada@m-kanazawa.jp

M. Haneda
Department of Medicine, Asahikawa Medical University,
Asahikawa, Japan

K. Furuichi · M. Shimizu · T. Toyama · A. Hara
Department of Disease Control and Homeostasis, Institute of
Medical, Pharmaceutical and Health Sciences, Kanazawa
University, Kanazawa, Japan

T. Babazono
Division of Nephrology and Hypertension, Diabetes Center,
Tokyo Women's Medical University School of Medicine,
Tokyo, Japan

H. Yokoyama
Jiyugaoka Medical Clinic, Internal Medicine, Obihiro, Japan

K. Iseki
Dialysis Unit, University Hospital of the Ryukyus, Nishihara,
Okinawa, Japan

S. Araki
Department of Medicine, Shiga University of Medical Science,
Otsu, Shiga, Japan

T. Ninomiya
Department of Medicine and Clinical Science, Graduate School
of Medical Sciences, Kyushu University, Fukuoka, Japan

S. Hara
Center of Health Management, Toranomon Hospital, Tokyo,
Japan

Y. Suzuki
Health Administration Center, Niigata University, Niigata, Japan

M. Iwano
Division of Nephrology, Department of General Medicine,
University of Fukui, Fukui, Japan

E. Kusano
Division of Nephrology, Department of Internal Medicine, Jichi
Medical University, Tochigi, Japan